Table 4 Bispecific antibodies in a clinical trial for BTKi-resistant MCL
Bispecific antibody (Company) | Trial Name | Target on T/B cells | Combinatorial agent | Study (N) | Outcomes | Adverse events | CT identifier (Ref) |
|---|---|---|---|---|---|---|---|
Blinatumomab (Amgen Research) | MT103-104 | CD3, CD19 | – | R/R MCL Phase 1 (24) | ORR 71% | Grade 1–3 NE 22% | NCT00274742 [192] |
NVG-111 (NovalGen Ltd.) | – | CD3 ROR-1 | – | MCL and other B-NHL Phase 1 (90) | Recruiting | Recruiting | NCT04763083 |
Mosunetuzumab (Genentech, Inc.) | GO29781 | CD3 CD20 | Atezolizumab | R/R MCL Phase 2 (13) | ORR 30.8% CR 23% | Grade 3 Neutropenia | NCT02500407 |
Glofitamab (Hoffmann-La Roche) | GO41944 | CD3 CD20 | Obinutuzumab | R/R MCL Phase 1/2 (37) | ORR 83.8% CR 73% | Grade 1–2 NE 51.5% CRS 75.7% | NCT03075696 |
Glofitamab (The Lymphoma Academic Research Organisation) | – | CD3 CD20 | Obinutuzumab | MCL and other B-NHL Phase 2 (78) | Recruiting | Recruiting | NCT04703686 |
Epcoritamab (Genmab) | EPCORE NHL-1 trial | CD3 CD20 | – | R/R MCL Phase 1/2 (4) | ORR 50% CR 25% | CRS (49.7%); grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%) | NCT03625037 [193] |
Odronextamab (Regeneron Pharmaceuticals) | ELM-1 | CD3 CD20 | – | R/R MCL Phase 1/2 (78) | ORR 57.9% | Anemia and lymphopenia | NCT02290951 [194] |
PSB202 (Qilu Puget Sound Biotherapeutics) | – | CD20 CD37 | – | MCL and other B-NHL Phase 1 (110) | Recruiting | Recruiting | NCT05003141 |
IGM-2323 (IGM Biosciences, Inc) | – | CD3 CD20 | – | MCL and other B-NHL Phase 1/2 (260) | Recruiting | Recruiting | NCT04082936 |
GEN3009 (Genmab) | – | CD37 CD3 CD20 | Epcoritamab | MCL and other B-NHL Phase 1/2 (182) | Recruiting | Recruiting | NCT04358458 |
Plamotamab (Xencor, Inc.) | – | CD3 CD20 | – | MCL and other B-NHL Phase 1/2 (182) | Recruiting | Recruiting | NCT02924402 |